Breaking News on Food & Beverage Development - EuropeUS edition | Asian edition

News > Policy


Dietary supplement linked to liver damage


The US Food and Drug Administration (FDA) warned consumers this week to stop using the dietary supplement Lipokinetix®.

According to the FDA the supplement has been implicated in a number of serious liver injuries. The Administration has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix.

Lipokinetix is marketed for weight loss and contains the ingredients norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of Lipokinetix. Liver injury developed between 2 weeks and 3 months of Lipokinetix use.

The FDA urged consumers to discontinue use of Lipokinetix and to consult their doctors if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin colour.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Live Supplier Webinars

Rethinking Fat Forum
William Reed Business Media

On demand Supplier Webinars

Your future starts at Cargill's T for Trends
Cargill Cocoa & Chocolate
Food testing — let automation take the strain
ETENIA™: Recognize True Milk Value
The FoodNavigator Salt Reduction Forum
William Reed Business Media
All supplier webinars